Increased cholinergic activity under conditions of low estrogen leads to adverse cardiac remodeling
- 1 April 2021
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 320 (4) , C602-C612
Abstract
Cholinesterase inhibitors are used in postmenopausal women for the treatment of neurodegenerative diseases. Despite their widespread use in the clinical practice, little is known about the impact of augmented cholinergic signaling on cardiac function under reduced estrogen conditions. To address this gap, we subjected a genetically engineered murine model of systemic vesicular acetylcholine transporter overexpression ( Chat-ChR2) to ovariectomy and evaluated cardiac parameters. Left-ventricular function was similar between Chat-ChR2 and wild-type (WT) mice. Following ovariectomy, WT mice showed signs of cardiac hypertrophy. Conversely, ovariectomized (OVX) Chat-ChR2 mice evolved to cardiac dilation and failure. Transcript levels for cardiac stress markers atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) were similarly upregulated in WT/OVX and Chat-ChR2/OVX mice. 17β-Estradiol (E2) treatment normalized cardiac parameters in Chat-ChR2/OVX to the Chat-ChR2/SHAM levels, providing a link between E2 status and the aggravated cardiac response in this model. To investigate the cellular basis underlying the cardiac alterations, ventricular myocytes were isolated and their cellular area and contractility were assessed. Myocytes from WT/OVX mice were wider than WT/SHAM, an indicative of concentric hypertrophy, but their fractional shortening was similar. Conversely, Chat-ChR2/OVX myocytes were elongated and presented contractile dysfunction. E2 treatment again prevented the structural and functional changes in Chat-ChR2/OVX myocytes. We conclude that hypercholinergic mice under reduced estrogen conditions do not develop concentric hypertrophy, a critical compensatory adaptation, evolving toward cardiac dilation and failure. This study emphasizes the importance of understanding the consequences of cholinesterase inhibition, used clinically to treat dementia, for cardiac function in postmenopausal women.Keywords
Funding Information
- FAPEMIG (RED-00282-16)
- CNPq (423465/2018-0)
- FAPEMIG (APQ-01553-15)
- Pró-reitoria de Pesquisa da Universidade Federal de Minas Gerais
This publication has 43 references indexed in Scilit:
- Rising Heart Risks for Young Women Linked to Low Estrogen2019
- The non-neuronal cholinergic system in the heart: A comprehensive reviewJournal of Molecular and Cellular Cardiology, 2018
- Cardiac acetylcholine inhibits ventricular remodeling and dysfunction under pathologic conditionsThe FASEB Journal, 2015
- Pyridostigmine Restores Cardiac Autonomic Balance after Small Myocardial Infarction in MicePLOS ONE, 2014
- Cholinergic Signaling Exerts Protective Effects in Models of Sympathetic Hyperactivity-Induced Cardiac DysfunctionPLOS ONE, 2014
- Cholinergic Activity as a New Target in Diseases of the HeartMolecular Medicine, 2014
- The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's diseaseEuropean Heart Journal, 2013
- A review on cholinesterase inhibitors for Alzheimer’s diseaseArchives of Pharmacal Research, 2013
- Heart‐Specific Overexpression of Choline Acetyltransferase Gene Protects Murine Heart Against Ischemia Through Hypoxia‐Inducible Factor‐1α–Related Defense MechanismsJournal of the American Heart Association, 2013
- Cholinergic Stimulation Improves Autonomic and Hemodynamic Profile During Dynamic Exercise in Patients With Heart FailureJournal of Cardiac Failure, 2009